Hao Hu

About Hao Hu
  • Dr. Hu’s research program will focus on the mechanisms of prostate cancer initiation and progression. He and his team have identified the protein EMI1 (Early Mitotic Inhibitor 1) as playing a crucial role in disease development and progression by interacting with the androgen receptor, the primary driver of prostate cancer.
  • His team will study the role of EMI1 on the progression of prostate cancer to disease that is resistant to treatment.
  • Inactivation of EMI1 may be a therapeutic strategy against the development and progression of treatment- resistant prostate cancer.

What this means to patients: EMI1 represents a potential target for new drug development. If successful, patients would have a new therapy to prevent resistance to treatment of advanced disease.

Award

2013 PCF China Young Investigator in Honor of Stanley Zax

Hao Hu, MD, MBBS

People’s Hospital, Peking University

Mentors:

Kexin Xu, MD, MBBS and Xiaofeng Wang, MBBS

Project Title:

EMI1 and its role in prostate cancer initiation and progression.